Doximity Guides 4% FY27 Growth Despite Rapid AI Adoption, Shares Oversold
DOCS•Doximity reported FY26 revenue growth with margin compression and guided FY27 revenue up just 4% with EBITDA margins pressured by ramped AI investments, despite rapid adoption of its clinical AI tools. Shares tumbled 25.7% over four weeks, becoming technically oversold as analysts raise earnings estimates.
1. Mixed FY26 Results and Margin Compression
Doximity delivered solid FY26 revenue growth but saw operating margins narrow due to increased spending on AI development and clinical tool integration, driving margin compression across key product lines.
2. Accelerating AI Engagement but Monetization Lagging
The company experienced rapid adoption of its AI-driven clinical tools and strong enterprise traction, yet regulatory hurdles and operational friction continue to delay full monetization of these services.
3. Weak FY27 Guidance as AI Investments Ramp
Management set FY27 revenue growth guidance at just 4% and forecast further EBITDA margin compression as it scales AI capabilities, positioning the year as a transition phase.
4. Technical Oversold Condition and Analyst Estimate Revisions
Shares have dropped 25.7% over the past four weeks to oversold technical levels, prompting multiple analysts to lift earnings projections in anticipation of a potential stock rebound.
